Seletracetam

Summary

Seletracetam (CHEMBL3918017) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including epilepsy and focal epilepsy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 232.23 Da · C10H14F2N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3918017
Name	Seletracetam
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9942725
Molecular formula	C10H14F2N2O2
Molecular weight	232.23
InChIKey	ANWPENAPCIFDSZ-RQJHMYQMSA-N

SMILES: CC[C@@H](C(=O)N)N1C[C@@H](CC1=O)C=C(F)F

IUPAC name: (2S)-2-[(4S)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide

Also known as: Seletracetam, UCB 44212, UCB-44212, SELETRACETAM

Patent coverage: 284 distinct patent families (1,270 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
epilepsy	3	MONDO:0005027	EFO:0000474
focal epilepsy	2	MONDO:0005384	EFO:0004263

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00422110	PHASE2/PHASE3	WITHDRAWN	A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
NCT00152503	PHASE2	COMPLETED	Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).